Skip to main content

Table 3 Treatment-emergent adverse events occurring in ≥10% of patients in phase 1 (n = 43)

From: Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Treatment-emergent AEs, n (%) 100 mg 150 mg 200 mg 300 mg 400 mg 500 mg 600 mg All patients
n = 3 n = 6 n = 9 n = 6 n = 6 n = 7 n = 6 n = 43
Grade 1/2a Grade 3/4a
Any AE 3 (100.0) 6 (100.0) 9 (100.0) 6 (100.0) 6 (100.0) 7 (100.0) 6 (100.0) 8 (18.6) 35 (81.4)
Diarrhea 2 (66.7) 2 (33.3) 5 (55.6) 3 (50.0) 6 (100.0) 7 (100.0) 6 (100.0) 28 (65.1) 3 (7.0)
Nausea 0 1 (16.7) 2 (22.2) 3 (50.0) 4 (66.7) 5 (71.4) 4 (66.7) 19 (44.2) 0
Vomiting 0 1 (16.7) 4 (44.4) 2 (33.3) 3 (50.0) 3 (42.9) 3 (50.0) 16 (37.2) 0
Fatigue 1 (33.3) 1 (16.7) 3 (33.3) 2 (33.3) 2 (33.3) 3 (42.9) 1 (16.7) 9 (20.9) 4 (9.3)
Edema peripheral 2 (66.7) 2 (33.3) 1 (11.1) 0 2 (33.3) 2 (28.6) 3 (50.0) 10 (23.3) 2 (4.7)
Pyrexia 1 (33.3) 2 (33.3) 2 (22.2) 1 (16.7) 2 (33.3) 2 (28.6) 2 (33.3) 9 (20.9) 3 (7.0)
Anemia 0 1 (16.7) 1 (11.1) 1 (16.7) 2 (33.3) 2 (28.6) 3 (50.0) 3 (7.0) 7 (16.3)
Constipation 2 (66.7) 2 (33.3) 2 (22.2) 1 (16.7) 2 (33.3) 1 (14.3) 1 (16.7) 11 (25.6) 0
Abdominal distension 0 0 2 (22.2) 1 (16.7) 3 (50.0) 1 (14.3) 2 (33.3) 9 (20.9) 0
Dyspnea 2 (66.7) 1 (16.7) 0 0 2 (33.3) 1 (14.3) 3 (50.0) 9 (20.9) 0
Asthenia 2 (66.7) 2 (33.3) 1 (11.1) 0 0 1 (14.3) 2 (33.3) 6 (14.0) 2 (4.7)
Decreased appetite 2 (66.7) 2 (33.3) 0 0 3 (50.0) 0 1 (16.7) 8 (18.6) 0
Epistaxis 2 (66.7) 1 (16.7) 1 (11.1) 2 (33.3) 1 (16.7) 0 1 (16.7) 7 (16.3) 1 (2.3)
Thrombocytopenia 1 (33.3) 2 (33.3) 0 1 (16.7) 2 (33.3) 1 (14.3) 1 (16.7) 2 (4.7) 6 (14.0)
Abdominal pain 1 (33.3) 1 (16.7) 1 (11.1) 1 (16.7) 2 (33.3) 0 1 (16.7) 6 (14.0) 1 (2.3)
Back pain 1 (33.3) 2 (33.3) 0 1 (16.7) 2 (33.3) 1 (14.3) 0 7 (16.3) 0
Insomnia 1 (33.3) 1 (16.7) 2 (22.2) 1 (16.7) 1 (16.7) 1 (14.3) 0 7 (16.3) 0
Hyperuricemia 1 (33.3) 1 (16.7) 0 0 0 1 (14.3) 3 (50.0) 5 (11.6) 1 (2.3)
Cardiac murmur 1 (33.3) 0 1 (11.1) 0 1 (16.7) 1 (14.3) 2 (33.3) 6 (14.0) 0
Dizziness 0 0 2 (22.2) 1 (16.7) 1 (16.7) 1 (14.3) 1 (16.7) 6 (14.0) 0
Night sweats 1 (33.3) 0 1 (11.1) 0 2 (33.3) 1 (14.3) 1 (16.7) 6 (14.0) 0
Neutropenia 1 (33.3) 2 (33.3) 0 1 (16.7) 1 (16.7) 0 0 2 (4.7) 3 (7.0)
Chills 0 2 (33.3) 0 0 1 (16.7) 1 (14.3) 1 (16.7) 5 (11.6) 0
Cough 1 (33.3) 1 (16.7) 1 (11.1) 1 (16.7) 1 (16.7) 0 0 5 (11.6) 0
Dehydration 0 1 (16.7) 0 0 2 (33.3) 1 (14.3) 1 (16.7) 5 (11.6) 0
Hyperbilirubinemia 1 (33.3) 1 (16.7) 1 (11.1) 1 (16.7) 1 (16.7) 0 0 5 (11.6) 0
Pain in extremity 3 (100.0) 0 0 1 (16.7) 0 0 1 (16.7) 5 (11.6) 0
Petechiae 2 (66.7) 2 (33.3) 0 0 0 1 (14.3) 0 5 (11.6) 0
Skin lesion 0 4 (66.7) 1 (11.1) 0 0 0 0 5 (11.6) 0
Upper respiratory tract infection 0 2 (33.3) 2 (22.2) 1 (16.7) 0 0 0 5 (11.6) 0
  1. aWorst grade during treatment
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us